Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-05204 in Metastatic Pancreatic Adenocarcinoma
NCT02329717Phase 2Unknown
- Sponsor
- Phoenix Biotechnology, Inc.
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nerium oleander extract in pancreatic adenocarcinoma (PDAC), sponsored by Phoenix Biotechnology, Inc. Primary endpoint: Overall Survival at 4.5 months. Status: unknown.
02
Drugs
nerium oleander extract
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02329717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329717.